Evidence map›Paper›PMID 36374112›Full record

ArticleMicrobiology resource announcements2022

Coding Complete Genome Sequence of the SARS-CoV-2 Virus Strain, Variant B.1.1, Sampled from Kazakhstan.

Yerbol Burashev, Bekbolat Usserbayev, Lespek Kutumbetov, Yergali Abduraimov, Markhabat Kassenov, Aslan Kerimbayev, Balzhan Myrzakhmetova, Aibarys Melisbek, Meirzhan Shirinbekov, Saken Khaidarov and 1 more

Abstract read
In one paragraph

Article in Microbiology resource announcements, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yerbol BurashevResearch Institute for Biological Safety Problems (RIBSP), Gvardeyskiy, Kazakhstan.ORCID 0000-0002-4701-1992
Bekbolat UsserbayevResearch Institute for Biological Safety Problems (RIBSP), Gvardeyskiy, Kazakhstan.
Lespek KutumbetovResearch Institute for Biological Safety Problems (RIBSP), Gvardeyskiy, Kazakhstan.
Yergali AbduraimovResearch Institute for Biological Safety Problems (RIBSP), Gvardeyskiy, Kazakhstan.
Markhabat KassenovResearch Institute for Biological Safety Problems (RIBSP), Gvardeyskiy, Kazakhstan.
Aslan KerimbayevResearch Institute for Biological Safety Problems (RIBSP), Gvardeyskiy, Kazakhstan.
Balzhan MyrzakhmetovaResearch Institute for Biological Safety Problems (RIBSP), Gvardeyskiy, Kazakhstan.
Aibarys MelisbekResearch Institute for Biological Safety Problems (RIBSP), Gvardeyskiy, Kazakhstan.
Meirzhan ShirinbekovResearch Institute for Biological Safety Problems (RIBSP), Gvardeyskiy, Kazakhstan.
Saken KhaidarovFaculty of Biology and Biotechnology, Al-Farabi Kazakh National University, Almaty, Kazakhstan.
Edan R TulmanDepartment of Pathobiology and Veterinary Science and Center of Excellence for Vaccine Research, University of Connecticut, Storrs, Connecticut, USA.

Funding

Ministry of Education and Science of the Republic of Kazakhstan (Ministry of Education and Science, Republic of Kazakhstan) AP09058338 "STUDY OF ANTI-VIRAL ACTIVITY OF DRUGS AGAINST SARS-COV-2 VIRUS IN VITRO."
6 · The paper itself

Abstract

This article describes the results of sequencing and analysis of the entire genome of the SARS-CoV-2 virus sampled in Kazakhstan in 2021. The whole-genome sequence of the strain was 29,751 bp. According to the results of phylogenetic analysis (according to the Pangolin COVID-19 database), the SARS-CoV-2/human/KAZ/B1.1/2021 strain studied here was assigned to variant B.1.1.

Identifiers

PMID36374112
PMCPMC9753645

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.